Such is the case with newly approved Bristol-Myers Squibb drug Cobenfy. The underlying drug was first studied in Alzheimer’s ...

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...

Schizoid personality disorder can include constant daydreaming, but unlike schizophrenia, the daydreaming of schizoid personality disorder does not include hallucinations or a complete disconnect with ...

In a revealing Genomic Press Interview, Professor Illana Gozes discusses her groundbreaking work on activity-dependent ...

While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?

A new type of schizophrenia drug developed by Boston biotech Karuna Therapeutics won approval from the U.S. Food and Drug ...

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

Patients with schizophrenia are “all treated with pretty much the same medicines that work the same way,” Samit Hirawat, ...

"The MDPS is an update to decades old surveys of psychiatric disorders in the U.S. It had a focus on identifying schizophrenia spectrum disorders by administering the Structured Clinical Interview for ...

A total of 70 individuals with first-episode schizophrenia were prospectively enrolled between December 2022 and November 2023. Diagnostic evaluation was conducted by a psychiatrist using the ...

"The MDPS is an update to decades old surveys of psychiatric disorders in the U.S. It had a focus on identifying schizophrenia spectrum disorders by administering the Structured Clinical Interview ...

(AP Photo/David Zalubowski) Prosecutors seeking to convict a schizophrenic man in the killings of 10 people inside a Boulder King Soopers implored a jury during closing arguments Friday to remember ...